Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
?1.83

?1.83

 
WKN: A2PL3P / Symbol: ONCT / Name: Oncternal Therapeutics / Stock / Small Cap /
Latest predictions
€27.72
29.01.24
-
buy
26.01.24
-
18.01.24
-
€1.81
27.12.23
-41.48%
buy
25.12.23
-41.48%
17.12.23
-16.35%
Your prediction

Oncternal Therapeutics Inc. Stock

Certainly not a favorite of our community, Oncternal Therapeutics Inc. currently has 21 Sell predictions and 3 Buy predictions.
However, we have a potential of 216.46% for Oncternal Therapeutics Inc. as the target price of 1 € is above the current price of 0.32 €.
For the coming years our community has positive and negative things to say abot the Oncternal Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.

Pros and Cons of Oncternal Therapeutics Inc. in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Prediction Buy
Perf. (%) -
Target price 27.720
Change
Ends at 29.01.25

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target raised by analysts at HC Wainwright to $30.00. They now have a "buy" rating on the stock.
Ratings data for ONCT provided by MarketBeat
Show more

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat
Show more

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat
Show more